A citation-based method for searching scientific literature

Sean P Cleary, William R Jeck, Xiaobei Zhao, Kui Chen, Sara R Selitsky, Gleb L Savich, Ting-Xu Tan, Michael C Wu, Gad Getz, Michael S Lawrence, Joel S Parker, Jinyu Li, Scott Powers, Hyeja Kim, Sandra Fischer, Maha Guindi, Anand Ghanekar, Derek Y Chiang. Hepatology 2013
Times Cited: 183







List of co-cited articles
908 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.
Cécile Guichard, Giuliana Amaddeo, Sandrine Imbeaud, Yannick Ladeiro, Laura Pelletier, Ichrafe Ben Maad, Julien Calderaro, Paulette Bioulac-Sage, Mélanie Letexier, Françoise Degos,[...]. Nat Genet 2012
818
60

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.
Kornelius Schulze, Sandrine Imbeaud, Eric Letouzé, Ludmil B Alexandrov, Julien Calderaro, Sandra Rebouissou, Gabrielle Couchy, Clément Meiller, Jayendra Shinde, Frederic Soysouvanh,[...]. Nat Genet 2015
717
44

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.
Yasushi Totoki, Kenji Tatsuno, Kyle R Covington, Hiroki Ueda, Chad J Creighton, Mamoru Kato, Shingo Tsuji, Lawrence A Donehower, Betty L Slagle, Hiromi Nakamura,[...]. Nat Genet 2014
385
38

Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.
Zhengyan Kan, Hancheng Zheng, Xiao Liu, Shuyu Li, Thomas D Barber, Zhuolin Gong, Huan Gao, Ke Hao, Melinda D Willard, Jiangchun Xu,[...]. Genome Res 2013
308
33

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.
Akihiro Fujimoto, Yasushi Totoki, Tetsuo Abe, Keith A Boroevich, Fumie Hosoda, Ha Hai Nguyen, Masayuki Aoki, Naoya Hosono, Michiaki Kubo, Fuyuki Miya,[...]. Nat Genet 2012
557
31

Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.
Sung-Min Ahn, Se Jin Jang, Ju Hyun Shim, Deokhoon Kim, Seung-Mo Hong, Chang Ohk Sung, Daehyun Baek, Farhan Haq, Adnan Ahmad Ansari, Sun Young Lee,[...]. Hepatology 2014
199
28


Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner,[...]. N Engl J Med 2008
21

Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer.
Akihiro Fujimoto, Mayuko Furuta, Yasushi Totoki, Tatsuhiko Tsunoda, Mamoru Kato, Yuichi Shiraishi, Hiroko Tanaka, Hiroaki Taniguchi, Yoshiiku Kawakami, Masaki Ueno,[...]. Nat Genet 2016
317
20

Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma.
Jian Huang, Qing Deng, Qun Wang, Kun-Yu Li, Ji-Hong Dai, Niu Li, Zhi-Dong Zhu, Bo Zhou, Xiao-Yan Liu, Rui-Fang Liu,[...]. Nat Genet 2012
253
16

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder,[...]. Lancet 2017
14

Diverse modes of genomic alteration in hepatocellular carcinoma.
Suchit Jhunjhunwala, Zhaoshi Jiang, Eric W Stawiski, Florian Gnad, Jinfeng Liu, Oleg Mayba, Pan Du, Jingyu Diao, Stephanie Johnson, Kwong-Fai Wong,[...]. Genome Biol 2014
61
21

Global cancer statistics, 2012.
Lindsey A Torre, Freddie Bray, Rebecca L Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal. CA Cancer J Clin 2015
12

Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.
Jessica Zucman-Rossi, Augusto Villanueva, Jean-Charles Nault, Josep M Llovet. Gastroenterology 2015
497
12

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
12

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma.
Meng Li, Hong Zhao, Xiaosong Zhang, Laura D Wood, Robert A Anders, Michael A Choti, Timothy M Pawlik, Hubert D Daniel, Rajesh Kannangai, G Johan A Offerhaus,[...]. Nat Genet 2011
277
11

Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma.
Wing-Kin Sung, Hancheng Zheng, Shuyu Li, Ronghua Chen, Xiao Liu, Yingrui Li, Nikki P Lee, Wah H Lee, Pramila N Ariyaratne, Chandana Tennakoon,[...]. Nat Genet 2012
502
11

Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.
Hyun Goo Woo, Xin Wei Wang, Anuradha Budhu, Yun Hee Kim, So Mee Kwon, Zhao-You Tang, Zongtang Sun, Curtis C Harris, Snorri S Thorgeirsson. Gastroenterology 2011
82
12

High-resolution characterization of a hepatocellular carcinoma genome.
Yasushi Totoki, Kenji Tatsuno, Shogo Yamamoto, Yasuhito Arai, Fumie Hosoda, Shumpei Ishikawa, Shuichi Tsutsumi, Kohtaro Sonoda, Hirohiko Totsuka, Takuya Shirakihara,[...]. Nat Genet 2011
200
10

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Parkin, David Forman, Freddie Bray. Int J Cancer 2015
10

Management of hepatocellular carcinoma: an update.
Jordi Bruix, Morris Sherman. Hepatology 2011
10

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Jean Charles Nault, Maxime Mallet, Camilla Pilati, Julien Calderaro, Paulette Bioulac-Sage, Christophe Laurent, Alexis Laurent, Daniel Cherqui, Charles Balabaud, Jessica Zucman-Rossi. Nat Commun 2013
342
10

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Jörg Trojan, Theodore H Welling,[...]. Lancet 2017
10

Genetic profiling of hepatocellular carcinoma using next-generation sequencing.
Kornelius Schulze, Jean-Charles Nault, Augusto Villanueva. J Hepatol 2016
103
9

Integrated analysis of whole genome and transcriptome sequencing reveals diverse transcriptomic aberrations driven by somatic genomic changes in liver cancers.
Yuichi Shiraishi, Akihiro Fujimoto, Mayuko Furuta, Hiroko Tanaka, Ken-ichi Chiba, Keith A Boroevich, Tetsuo Abe, Yoshiiku Kawakami, Masaki Ueno, Kunihito Gotoh,[...]. PLoS One 2014
44
20

Hepatocellular carcinoma.
Alejandro Forner, Josep M Llovet, Jordi Bruix. Lancet 2012
9

Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis.
Patrizia Zavattari, Andrea Perra, Silvia Menegon, Marta Anna Kowalik, Annalisa Petrelli, Maria Maddalena Angioni, Antonia Follenzi, Luca Quagliata, Giovanna Maria Ledda-Columbano, Luigi Terracciano,[...]. Hepatology 2015
54
16

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
9

Hepatocellular carcinoma.
Josep M Llovet, Jessica Zucman-Rossi, Eli Pikarsky, Bruno Sangro, Myron Schwartz, Morris Sherman, Gregory Gores. Nat Rev Dis Primers 2016
878
9

Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain.
K Itoh, N Wakabayashi, Y Katoh, T Ishii, K Igarashi, J D Engel, M Yamamoto. Genes Dev 1999
9

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Masatoshi Kudo, Richard S Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari Baron, Joong-Won Park, Guohong Han, Jacek Jassem,[...]. Lancet 2018
9


Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Rongcheng Luo, Jifeng Feng, Shenglong Ye, Tsai-Sheng Yang,[...]. Lancet Oncol 2009
8


NRF2 and cancer: the good, the bad and the importance of context.
Michael B Sporn, Karen T Liby. Nat Rev Cancer 2012
596
8

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.
Hashem B El-Serag, K Lenhard Rudolph. Gastroenterology 2007
8

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
Yujin Hoshida, Sebastian M B Nijman, Masahiro Kobayashi, Jennifer A Chan, Jean-Philippe Brunet, Derek Y Chiang, Augusto Villanueva, Philippa Newell, Kenji Ikeda, Masaji Hashimoto,[...]. Cancer Res 2009
567
8

Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
Jean Charles Nault, Julien Calderaro, Luca Di Tommaso, Charles Balabaud, Elie Serge Zafrani, Paulette Bioulac-Sage, Massimo Roncalli, Jessica Zucman-Rossi. Hepatology 2014
165
8

p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming.
Tetsuya Saito, Yoshinobu Ichimura, Keiko Taguchi, Takafumi Suzuki, Tsunehiro Mizushima, Kenji Takagi, Yuki Hirose, Masayuki Nagahashi, Tetsuro Iso, Toshiaki Fukutomi,[...]. Nat Commun 2016
146
8

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
Sandrine Boyault, David S Rickman, Aurélien de Reyniès, Charles Balabaud, Sandra Rebouissou, Emmanuelle Jeannot, Aurélie Hérault, Jean Saric, Jacques Belghiti, Dominique Franco,[...]. Hepatology 2007
634
7


Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming.
Yoichiro Mitsuishi, Keiko Taguchi, Yukie Kawatani, Tatsuhiro Shibata, Toshihiro Nukiwa, Hiroyuki Aburatani, Masayuki Yamamoto, Hozumi Motohashi. Cancer Cell 2012
708
7

The Dual Roles of NRF2 in Cancer.
Silvia Menegon, Amedeo Columbano, Silvia Giordano. Trends Mol Med 2016
276
7

The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1.
Masaaki Komatsu, Hirofumi Kurokawa, Satoshi Waguri, Keiko Taguchi, Akira Kobayashi, Yoshinobu Ichimura, Yu-Shin Sou, Izumi Ueno, Ayako Sakamoto, Kit I Tong,[...]. Nat Cell Biol 2010
7

Hepatocellular carcinoma.
Hashem B El-Serag. N Engl J Med 2011
7

Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma.
Mingxin Zhang, Chao Zhang, Lingmin Zhang, Qi Yang, Suna Zhou, Qinsheng Wen, Jingjie Wang. BMC Cancer 2015
69
10

Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Julien Calderaro, Gabrielle Couchy, Sandrine Imbeaud, Giuliana Amaddeo, Eric Letouzé, Jean-Frédéric Blanc, Christophe Laurent, Yacine Hajji, Daniel Azoulay, Paulette Bioulac-Sage,[...]. J Hepatol 2017
193
7

Targeting bromodomains: epigenetic readers of lysine acetylation.
Panagis Filippakopoulos, Stefan Knapp. Nat Rev Drug Discov 2014
712
6

Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Fukiko Kawai-Kitahata, Yasuhiro Asahina, Shinji Tanaka, Sei Kakinuma, Miyako Murakawa, Sayuri Nitta, Takako Watanabe, Satoshi Otani, Miki Taniguchi, Fumio Goto,[...]. J Gastroenterol 2016
46
13

Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity.
Akihiro Fujimoto, Mayuko Furuta, Yuichi Shiraishi, Kunihito Gotoh, Yoshiiku Kawakami, Koji Arihiro, Toru Nakamura, Masaki Ueno, Shun-ichi Ariizumi, Ha Hai Nguyen,[...]. Nat Commun 2015
107
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.